Global Transarterial Chemoembolization (TACE) Market, By Procedure Type (Conventional TACE, DEB-TACE), Product Type (Chemotherapeutic Agents, Radiotherapeutic Agents, Drug-eluting Particles), Indication (Unresectable HCC, Early-Stage HCC), End-User (Hospitals & Clinics, Cancer Research Centers), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights of Global Transarterial Chemoembolization (TACE) Market
Global transarterial chemoembolization (TACE) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 3,404.56 million by 2028 growing at a CAGR of 8.25% in the above-mentioned forecast period. Increasing expenditure in pharmaceutical industries and research and development has resulted in driving the transarterial chemoembolization (TACE) market.
Transarterial chemoembolization is a process to treat liver cancer. It works on basis of blocking the blood supply to the tumour. Once the supply is blocked, chemotherapy is given right into the tumour. It is a therapy for the patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional transarterial chemoembolization is considered as a standard treatment for HCC. Transarterial chemoembolization also uses microspheres as drug carriers, which helps to reduce the concentration of chemotherapeutic in the systemic circulation of patients.
Growing prevalence of hepatocellular carcinoma (HCC) has an annual surge of approximately 750,000 cases per year worldwide. Its graphs continues to increase due to the incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Constant growth of drug consumption and development is another driving factor for transarterial chemoembolization (TACE) market.
Complications after embolization and a higher cost of treatment is a challenge for transarterial chemoembolization (TACE) market. However, death of a skilled professional during the treatment is expected to restrain the market growth during the forecast period of 2021-2028.
This transarterial chemoembolization (TACE) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research transarterial chemoembolization (TACE) market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Transarterial Chemoembolization (TACE) Market Scope and Market Size
Transarterial chemoembolization (TACE) market is segmented on the basis of procedure type, product type, indication and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on procedure type, the transarterial chemoembolization (TACE) market is segmented into conventional TACE and DEB-TACE.
- Based on product type, the transarterial chemoembolization (TACE) market is segmented into chemotherapeutic agents, radiotherapeutic agents and drug-eluting particles.
- Transarterial chemoembolization (TACE) market is also segmented on basis of indication into unresectable HCC and early-stage HCC.
- On the basis of end-user, the transarterial chemoembolization (TACE) market is segmented into hospitals & clinics and cancer research centers.
Transarterial Chemoembolization (TACE) Market Country Level Analysis
Transarterial chemoembolization (TACE) market is analysed and market size insights and trends are provided by country, procedure type, product type, indication and end-user as referenced above.
The countries covered in the transarterial chemoembolization (TACE) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is likely to lead the transarterial chemoembolization (TACE) market. Increasing awareness about HCC (hepatocellular carcinoma) and early diagnosis for the disease are also boosting the transarterial chemoembolization (TACE) market in this country. Increased research and development funding is also propelling the transarterial chemoembolization (TACE) market growth in the region. The market in Asia-Pacific is expected to exhibit a substantial growth rate during the forecast period 2021-2028 due to the increasing rate of HCC in this region. Hepatitis C remains the main factor in Japan while hepatocellular carcinoma is attributable to hepatitis B virus which covers most of Asia.
The country section of the transarterial chemoembolization (TACE) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Transarterial chemoembolization (TACE) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for transarterial chemoembolization (TACE) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the transarterial chemoembolization (TACE) market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Transarterial Chemoembolization (TACE) Market Share Analysis
Transarterial chemoembolization (TACE) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to transarterial chemoembolization (TACE) market.
The major players covered in the transarterial chemoembolization (TACE) market report are Questex LLC., Siemens Healthcare GmbH, Intermountain Healthcare, Provincial Health Services Authority, Cancer Research Institute, Advaxis Inc., Bellicum Pharmaceuticals Inc., Boston Scientific Corporation, Cook, Hikma Pharmaceuticals PLC, Isofol Medical AB (publ) Biotech Center , Nippon Kayaku Co. Ltd., Novartis AG, Pfizer Inc., Sirtex SIR-Spheres Pty Ltd., Spectrum Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, CELGENE CORPORATION, Bayer AG, Hepion Pharmaceuticals , Polaris Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., and Merck & Co., Inc. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-